![]() |
7TM (Denmark) focuses on the discovery and development of peptides and small molecules for obesity, based on core expertise in seven transmembrane receptors and disease biology.
http://www.7tm.com |
![]() |
Ablynx (Belgium) is engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases including inflammation, thrombosis, oncology and Alzheimer’s disease.
http://www.ablynx.com |
![]() |
Addex (Switzerland) discovers and develops novel therapeutics which modulate the effect of natural activators of G-protein coupled receptors on their specific targets. These allosteric modulators offer the potential for novel, more selective and safer treatments for CNS and other disorders.
http://www.addexpharma.com |
![]() |
Algeta ASA (Norway) develops alpha particle emitters as radio- pharmaceuticals for the treatment of prostate cancer and other metastatic tumor types for which there is substantial unmet medical need. http://www.algeta.no |
![]() |
Anesiva (USA) is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain.
http://www.anesiva.com/ |
![]() |
Avantium (Netherlands) provides product and process development services to the chemical and pharmaceutical sectors.
http://www.avantium.com |
|
|
CalciMedica (USA) is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune and inflammatory diseases. A significant focus of the company’s drug discovery strategy is based on the specific inhibition of calcium release-activated calcium (CRAC) channels. http://www.calcimedica.com |
![]() |
CoNCERT Pharmaceuticals, Inc (USA) creates new drugs by using precision deuterium chemistry to modify the pharmacology of existing and new small molecule compounds to create a treatment benefit. http://www.concertpharma.com |
![]() |
CyDex (USA) develops and commercializes specialty
pharmaceutical products based on drug delivery and
formulation technologies.
http://www.cydexinc.com |
| EPIX Pharmaceuticals (USA) is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform
http://www.epixpharma.com/ |
|
![]() |
Kosan Biosciences (USA) is a therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones.
http://www.kosan.com/ |
|
|
Lexicon (USA) is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. The company uses its proprietary gene knockout technology to disrupt the function of genes in mice and then employs an integrated platform to systematically discover the physiological and behavioral functions and pharmaceutical utility of the genes.
http://www.lexpharma.com/index.php |
![]() |
Locus Pharmaceuticals, Inc. (USA) applies its core fragment-based, computational drug design technology with its capabilities in medicinal chemistry, crystallography and biology to create small molecule product. The company has a portfolio of emerging candidates in development for cancer and inflammation.
http://www.locuspharma.com |
|
|
Memory Pharmaceuticals (USA) is a biotechnology company focused on developing innovative drugs for the treatment of debilitating central nervous system (CNS) disorders, many of which exhibit significant impairment of memory and other cognitive function.
http://www.memorypharma.com/ |
![]() |
Novalar Pharmaceuticals, Inc.(USA) is a specialty pharmaceutical company. Lead asset NV-101, for the reversal of numbness associated with local dental anesthesia, has completed Phase III trials. An NDA was filed in 2007.
http://www.novalarpharm.com |
![]() |
Nucleonics, Inc. (USA) is a drug discovery and development company that
is using proprietary RNAi technologies for the treatment of infectious
and other diseases.
http://www.nucleonicsinc.com |
|
|
OctoPlus NV (Netherlands) provides formulation services and develops proprietary products employing its patented implantable polymer microspheres for controlled drug delivery.
http://www.octoplus.nl |
![]() |
Onyvax, Inc. (UK) is developing allogeneic-cell based vaccines for the
treatment of cancer. The company has programs in clinical development
in prostate cancer.
http://www.onyvax.com |
|
|
PharmaKodex (UK) is an emerging speciality pharmaceuticals company that is developing a range of improved medicinal products (IMPS) with a focus on neurology an and emphasis on treatments for the young and elderly where special delivery can provide significant benefits such as ease of medication for patients and care-givers, rapid action onset and improved treatment outcomes.
http://www.pharmakodex.com |
![]() |
Protez Pharmaceuticals (USA) discovers and develops new anti-microbials
to combat the growing problem of drug resistance, as well as agents
that improve the efficacy of current antibiotics.
http://www.protez.com |
|
|
RedPoint Bio. (USA) develops gustation solutions, with a focus on products to improve bitter flavors and treatments for taste dysfunction. http://www.redpointbio.com |
![]() |
Resistentia Pharmaceuticals AB (Sweden) develops and commercializes
immunotherapies as second generation to monoclonal antibodies for the
treatment of chronic inflammatory diseases, including asthma and
allergy.
http://www.resistentia.se |
![]() |
Rib-X Pharmaceuticals (USA) is developing novel classes of anti-microbials to address
unmet needs in resistant community and hospital-acquired infections
using structure-based drug design and its proprietary knowledge of the
crystal structure of the 50S subunit of the ribosome and other
important targets.
http://www.rib-x.com |
![]() |
Scynexis, Inc. (USA) offers drug discovery and development services to
biotech and pharmaceutical companies through a suite of research,
development and products.
http://www.scynexis.com |
| Syntaxin Ltd. (UK) uses its substantial knowledge of microbial proteins and expertise in protein engineering to discover and develop novel biopharmaceuticals that block cell secretion in a variety of cell types for the treatment of pain, nervous, respiratory and metabolic diseases.
http://www.syntaxin.com |
|
| TorreyPines Therapeutics (USA) is a biopharmaceutical company committed to discovering, developing and commercializing novel small molecules to treat diseases and disorders of the central nervous system.
http://www.torreypinestherapeutics.com/home.php |
|
![]() |
Trinity Biosystems (USA) is using its novel platform of oral and nasal delivery to develop proteins and peptide therapeutics.
http://www.trinitybiosystems.com |
![]() |
Zelos Therapeutics (USA) is developing new treatments for
osteoporosis and other indications based on breakthrough discoveries in
parathyroid hormone research. Lead candidate Ostabolin C is in Phase II
trials.
http://www.zelostherapeutics.com |